Mereo BioPharma Group plc (MREO)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Revenue | 500 | - | - | |
| Research and development | 5,373 | 3,930 | 3,170 | |
| General and administrative | 5,494 | 7,272 | 6,203 | |
| Cost of revenue | 132 | - | - | |
| Loss from operations | -10,499 | -11,202 | -9,373 | |
| Interest income | 589 | 659 | 983 | |
| Interest expense | 24 | 180 | 353 | |
| Changes in the fair value of warrants | -101 | 416 | -59 | |
| Foreign currency transaction (loss)/gain, net | -5,326 | -2,765 | -6,425 | |
| Benefit from research and development tax credit | 745 | 185 | 226 | |
| Net loss before income tax | -14,616 | -12,887 | -15,001 | |
| Income tax benefit | - | - | - | |
| Net loss | -14,616 | -12,887 | -15,001 | |
| Other comprehensive income/(loss) - foreign currency translation adjustments, net of tax | 6,647 | 3,559 | 7,174 | |
| Total comprehensive loss | -7,969 | -9,328 | -7,827 | |
| Earnings per share, basic | -0.02 | -0.02 | -0.02 | |
| Earnings per share, diluted | -0.02 | -0.02 | -0.02 | |
| Weighted average number of shares outstanding, basic | 799,435,329 | 784,279,387 | 770,146,589 | |
| Weighted average number of shares outstanding, diluted | 799,435,329 | 784,279,387 | 770,146,589 | |